Tech Company Financing Transactions
LeadArt Technologies Funding Round
On 1/2/2022, LeadArt Technologies secured $6 million in Series A funding from BlueRun Ventures.
Transaction Overview
Company Name
Announced On
1/2/2022
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series A
Investors
BlueRun Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance the development of its automated chemoproteomics platform and the creation of a human target-probe database.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building C3, Qidi Science and Technology Park, Zhongguan Wes
Ningbo, 315201
CN
Ningbo, 315201
CN
Phone
Undisclosed
Website
Email Address
Overview
LeadArt Biotechnologies Inc., founded in 2022, is a subsidiary company of Ningbo LeadArt Biotechnology Co., LTD., founded in 2017. LeadArt is the first biotechnology company in China and one of the few in the world that has mastered breakthrough chemical proteomics technology. The company also has mature biotechnology automation equipment development and proven productization capabilities. Powered with state-of-art biotechnology and advanced automation technology, LeadArt is building the largest and leading live cell target-probe database in the world and aspired to expand the drug target space and speed up drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Feng Ni
Co-Founder
JIe Yan
Co-Founder
Yufeng Zhao
Browse more venture capital transactions:
Prev: 1/1/2022: Finout venture capital transaction
Next: 1/3/2022: Concretene venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs